Literature DB >> 9830205

Dengue vaccine design: issues and challenges.

M J Cardosa1.   

Abstract

Dengue virus infection is now a global problem affecting tens of millions of people. The spread of the four dengue virus serotypes had led to increased incidence of dengue haemorrhagic fever (DHF) reported and with 2.5 billion people at risk, efforts towards the development of safe and effective vaccines against dengue must be accelerated. This chapter reviews some of the important lessons of pathogenesis which may be learnt from classical studies in the field and place these in the context of current knowledge about the molecular biology of the virus. The issues which have to be addressed in designing a safe vaccine against dengue are raised and the problems of designing subunit as well as whole virus vaccines are pointed out, particularly with regard to the phenomenon of antibody dependent enhancement and, more generally, the problem of immune potentiation of disease. More efforts must be made to understand the basis of pathogenesis in DHF and in finding out what nature has to teach about protection against and recovery from dengue virus infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9830205     DOI: 10.1093/oxfordjournals.bmb.a011696

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  5 in total

1.  Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus.

Authors:  A V Timofeev; V M Butenko; J R Stephenson
Journal:  Virus Genes       Date:  2004-01       Impact factor: 2.332

2.  High-resolution crystal structure of FKBP12 from Aedes aegypti.

Authors:  Sreekanth Rajan; Kai Qian Saw; Quoc Toan Nguyen; Kwanghee Baek; Ho Sup Yoon
Journal:  Protein Sci       Date:  2012-05-18       Impact factor: 6.725

3.  Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.

Authors:  David E Clements; Beth-Ann G Coller; Michael M Lieberman; Steven Ogata; Gordon Wang; Kent E Harada; J Robert Putnak; John M Ivy; Michael McDonell; Gary S Bignami; Iain D Peters; Julia Leung; Carolyn Weeks-Levy; Eileen T Nakano; Tom Humphreys
Journal:  Vaccine       Date:  2010-01-22       Impact factor: 3.641

4.  Development of Dengue virus type 2 replicons capable of prolonged expression in host cells.

Authors:  X Pang; M Zhang; A I Dayton
Journal:  BMC Microbiol       Date:  2001-08-24       Impact factor: 3.605

5.  Morphological Aspects and Viremia Analysis of BALB/c Murine Model Experimentally Infected with Dengue Virus Serotype 4.

Authors:  Arthur da Costa Rasinhas; Fernanda Cunha Jácome; Gabriela Cardoso Caldas; Ana Luisa Teixeira de Almeida; Marcos Alexandre Nunes da Silva; Daniel Dias Coutinho de Souza; Amanda Carlos Paulino; Derick Mendes Bandeira; Raphael Leonardo; Priscila Conrado Guerra Nunes; Ronaldo Mohana-Borges; Ortrud Monika Barth; Flavia Barreto Dos Santos; Debora Ferreira Barreto Vieira
Journal:  Viruses       Date:  2021-09-29       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.